/Investor DB

RiverVest Venture Partners — 2016 Investments

3 investments dated 2016 · listed companies and verified rows first · show all

AnTolRxantolrx.cominSeries A · Sep 2016 · $4M

AnTolRx develops immunotherapy therapeutics based on research in immune tolerance, targeting immune-mediated disorders.

BiotechHealthtechBoston, US

Francisco J. Quintana(Scientific Founder, Member of Board of Directors)Mark Carthy(Founder and CEO, Member of Board of Directors)

BoardSatish Jindal(Director)

Arch Oncology Incarchoncology.comSeries A · Aug 2016 · $86M

Co-investorsAvego BioScience CapitalBioGenerator VenturesPerot JainRoche Venture FundSR One Capital Management

Glycomineglycomine.comin𝕏Series B · Oct 2016 · $35M

Glycomine develops therapeutics for rare diseases, many of which currently lack disease-modifying treatment options.

BiotechSan Francisco, US

Agnes Rafalko(Executive Officer, Director)inSteven Axon(Chief Executive Officer)inHicham Alaoui(Chief Scientific Officer)inRose Marino(Chief Medical Officer)inPeter McWilliams(Chief Business Officer)Geoffrey Hird(Chief Technology Officer)in

Co-investorsAdvent Life SciencesAsahi Kasei Corporate Venture CapitalChiesi VenturesCTI Life Sciences Fund L.P.Mission Bay CapitalMission Biocapital+6 more

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.